These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 38365419

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial.
    Baisley K, Kemp TJ, Kreimer AR, Basu P, Changalucha J, Hildesheim A, Porras C, Whitworth H, Herrero R, Lacey CJ, Schiller JT, Lucas E, Mutani P, Dillner J, Indangasi J, Muwonge R, Hayes RJ, Pinto LA, Watson-Jones D.
    Lancet Glob Health; 2022 Oct; 10(10):e1485-e1493. PubMed ID: 36113532
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine.
    Godi A, Bissett SL, Miller E, Beddows S.
    PLoS One; 2015 Oct; 10(10):e0140926. PubMed ID: 26495976
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial.
    Sharma H, Parekh S, Pujari P, Shewale S, Desai S, Bhatla N, Joshi S, Pimple S, Kawade A, Balasubramani L, Thomas A, Suri V, Lalwani S, Uday R, Kamath V, Mandal R, Rajeswar A, Peedicayil A, Poli UR, Banerjee D, Sankaranarayanan R, Basu P, Muwonge R, Gairola S, Dogar V, Rao H, Shaligram U.
    Lancet Oncol; 2023 Dec; 24(12):1321-1333. PubMed ID: 37949086
    [Abstract] [Full Text] [Related]

  • 7. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study.
    Basu P, Malvi SG, Joshi S, Bhatla N, Muwonge R, Lucas E, Verma Y, Esmy PO, Poli URR, Shah A, Zomawia E, Pimple S, Jayant K, Hingmire S, Chiwate A, Divate U, Vashist S, Mishra G, Jadhav R, Siddiqi M, Sankaran S, Prabhu PR, Kannan TPRA, Varghese R, Shastri SS, Anantharaman D, Gheit T, Tommasino M, Sauvaget C, Pillai MR, Sankaranarayanan R.
    Lancet Oncol; 2021 Nov; 22(11):1518-1529. PubMed ID: 34634254
    [Abstract] [Full Text] [Related]

  • 8. Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE Study): study protocol for a randomized controlled trial.
    Barnabas RV, Brown ER, Onono M, Bukusi EA, Njoroge B, Winer RL, Donnell D, Galloway D, Cherne S, Heller K, Leingang H, Morrison S, Rechkina E, McClelland RS, Baeten JM, Celum C, Mugo N, KEN SHE Study Team.
    Trials; 2021 Sep 27; 22(1):661. PubMed ID: 34579786
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
    Barzon L, Squarzon L, Masiero S, Pacenti M, Marcati G, Mantelli B, Gabrielli L, Pascucci MG, Lazzarotto T, Caputo A, Palù G.
    Vaccine; 2014 Sep 15; 32(41):5357-62. PubMed ID: 25045814
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda.
    LaMontagne DS, Mugisha E, Pan Y, Kumakech E, Ssemaganda A, Kemp TJ, Cover J, Pinto LA, Safaeian M.
    Vaccine; 2014 Oct 29; 32(47):6303-11. PubMed ID: 25218297
    [Abstract] [Full Text] [Related]

  • 15. Two-dose schedules for human papillomavirus vaccine: Systematic review and meta-analysis.
    D'Addario M, Redmond S, Scott P, Egli-Gany D, Riveros-Balta AX, Henao Restrepo AM, Low N.
    Vaccine; 2017 May 19; 35(22):2892-2901. PubMed ID: 28455170
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine.
    Gilca V, Sauvageau C, Boulianne N, De Serres G, Crajden M, Ouakki M, Trevisan A, Dionne M.
    Hum Vaccin Immunother; 2015 May 19; 11(3):732-8. PubMed ID: 25714044
    [Abstract] [Full Text] [Related]

  • 19. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis.
    Donken R, Knol MJ, Bogaards JA, van der Klis FR, Meijer CJ, de Melker HE.
    J Infect; 2015 Jul 19; 71(1):61-73. PubMed ID: 25709084
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.